5 years ago

Myricx Pharma Secures £4.5 Million Seed Funding for Cancer Drug Development

  • Myricx Pharma, a UK-based drug discovery company focused on developing small molecule inhibitors that selectively target the human N-myristoyltransferases (NMT) in cancer, raised £4.5 million in seed financing

  • The funding was led by Sofinnova Partners and Brandon Capital Partners and will be used to advance discoveries in cancer and develop precision medicines for a range of diseases.

      • ProblemHealthcare

      "Cancer is a leading cause of death worldwide and there is a critical need for new treatments that are more effective and less toxic than current therapies."

      Solution

      "Myricx Pharma is developing small molecule inhibitors that selectively target the human N-myristoyltransferases (NMT) in cancer. These inhibitors are proving to be highly effective in the treatment of MYC-driven cancer models, which are particularly difficult to treat with existing therapies."

      Covered on